SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Más mercado (y víctimas) de la vacuna VPH

By Leave a Comment

Publicado por Miguel Jara el

Spain
13 de Septiembre de 2010

La campaña para expandir la polémica vacunación contra el virus del papiloma humano toma fuerza. Hasta ahora sólo se podía vacunar a las niñas pero la Comisión Europea ha extendido su administración a mujeres de hasta 45 años.

Hay algunas cosas que llaman la atención. La primera de ellas es que antes decían que esta vacuna estaba indicada para las jóvenes que no habían iniciado relaciones sexuales ya que según un estudio realizado con una de las marcas del preparado, Gardasil, del laboratorio Merck, si la joven estaba infectada había un 44,6% de posibilidades de contraer cáncer de útero. Ahora parece que obvian este estudio. Desde la Asociación de Afectadas por la Vacuna contra el Papiloma opinan:

“Creemos que este dato no se puede obviar y todas las mujeres deberían hacerse una citología o pruebas antes de recibir la vacuna para ver si están infectadas, de lo contrario en lugar de prevenir la hipotética posibilidad de contraer cáncer de útero, incrementarían esta posibilidad en un 44,6%“.

Natural Infectious Disease Declines; Immunization Effectiveness: and Immunization Dangers

By Leave a Comment

SYNOPTIC OVERVIEW:
ISSUES IN IMMUNIZATION THEORY AND PRACTICE

Prepared by: Raymond Obomsawin Ph.D.
October 2009

FIGURE SET 1. Natural Infectious Disease Declines Preceding Public Immunization Efforts

Figures one (I) through ten (IO) graphically illustrate that in North America, Europe, and the South Pacific, major declines in life-threatening infectious diseases occurred historically either without, or far in advance of public immunization efforts for specific diseases as listed. This provides irrefutable evidence that vaccines are not necessary for the effective elimination of a wide range of infectious diseases

FIGURE SET II. Immunization Effectiveness

Figures eleven (11) through nineteen (19) graphically illustrate that immunization is not by any means a proven and foolproof measure for protection from various infectious disease conditions. It is often inconsequential epidemiologically, and in some cases it is shown to actually worsen health-care outcomes.

FIGURE SET III. Immunization Dangers

Figures twenty (20) through twenty-nine (29) graphically illustrate that increases in the number of government mandated vaccines correlates with significant increases in death rates for children under the age of five (5); and that the practice is linked to sudden infant death syndrome; various degenerative diseases, including diabetes; and appears to cause general immune system impairment in infants and children. Evidence also points to the practice of immunization as a principal factor in the recent massive increases in neurodegenerative conditions such as autism in children.

Flu vaccine does not reduce risk of severe complications

By Leave a Comment

Food Consumer

09/11/2010

Editor’s note: For your information, food consumer is the first to report the study.

Italian researchers have discovered that the influenza vaccine does NOT reduce risk of severe complications from influenza viral infections that result in hospital death, influenza or pneumonia admission among the elderly population.

The finding came after Manzoli L. and colleagues from the University G. d’Annunzio of Chieti in Italy examined data from 32,457 elderly people, of whom 66.2 percent received the influenza vaccine.

According to a recent review, almost all flu vaccine trials, with the exception of one out of 49 of said trials, have not compared the incidence of flu in the vaccinated population with that in those unvaccinated.

Rather, subjects who received flu shots in influenza vaccine trials were only tested for antigens which were produced in response to flu vaccine. When a flu vaccine generated certain levels of antigens as defined by researchers, the vaccine maker claimed that the flu vaccine worked to prevent flu.

Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men.

By Leave a Comment

Pubmed
J Infect Dis. 2010 Sep 2

Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM.

Abstract
Background. Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer. Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types. Methods. AIDS Malignancy Consortium Protocol 052 is a single-arm, open-label, multicenter clinical trial to assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HIV-1-infected men. Men with high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded. Men received 0.5 mL intramuscularly at entry, week 8, and week 24. The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination. Results. There were no grade 3 or greater adverse events attributable to vaccination among the 109 men who received at least 1 vaccine dose. Seroconversion was observed for all 4 types: type 6 (59 [98%] of 60), type 11 (67 [99%] of 68), type 16 (62 [100%] of 62), and type 18 (74 [95%] of 78). No adverse effects on CD4 counts and plasma HIV-1 RNA levels were observed. Conclusions. The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1-infected men. Efficacy studies in HIV-1-infected men are warranted. Clinical trials registration. NCT 00513526 .

PMID: 20812850 [PubMed – as supplied by publisher]

Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy

By Leave a Comment

American Association for Cancer Research
Francesca M. Carozzi1, Maria L. Tornesello2, Elena Burroni1, Giovanna Loquercio2, Giuseppe Carillo3, Claudio Angeloni4, Aurora Scalisi5, Rosalba Macis6, Francesco Chini7, Franco M. Buonaguro2, Paolo Giorgi Rossi7 and for the HPV Prevalence Italian Working Group

Corresponding Author:
Paolo Giorgi Rossi, Laziosanità, Via di Santa Costanza, 53, Rome 00198, Italy. E-mail: giorgirossi@asplazio.it

Abstract

Background: The aim of this multicentric study was to identify human papillomavirus (HPV) type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia 2/3 (CIN2/3) in Italy.

Methods: Cases were sampled through the electronic databases at the pathology units of eight centers in six regions from central and southern Italy. HPV types were detected from paraffin-embedded tissue samples and cervical specimens through amplification of HPV DNA with GP5+/GP6+ primers, followed by genotyping with reverse line blot (RLB). Untyped HPV-positive samples were sequenced. HPV-negative samples underwent nested PCR, followed by either RLB or sequencing. Finally, the remaining HPV-negative samples were amplified with primers targeting the virus E6 to E7 regions.

News

Videos

Contact